PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
Synapse
⌘+K
Synapse
April 5, 2026Cancer Research

Abstract 5405: STX002: A GPC3-targeted antibody-drug conjugate with potent and durable antitumor activity in preclinical models of hepatocellular carcinoma.

View Full Paper
Ask AI
Bookmark
Share

Authors

DRDeepak RohilaSWSameena WaniATAtul K. Tandon

Discussion

Loading...

Member takes

Overview

Preclinical models demonstrate potent antitumor activity of GPC3-targeted ADC STX002 in hepatocellular carcinoma, indicating a promising therapeutic option.

Key Points

  • To evaluate the efficacy and safety of STX002, a GPC3-targeted antibody-drug conjugate, against hepatocellular carcinoma.
  • Developed humanized anti-GPC3 antibody conjugated to a topoisomerase I inhibitor.
  • Assessed binding and internalization in GPC3-positive cells.
  • Conducted in vivo studies using CDX and PDX models of HCC.
  • Evaluated pharmacokinetics and off-target toxicity.
  • STX002 exhibited potent cytotoxicity with sub-nanomolar IC50 values.
  • Produced significant tumor regressions in GPC3-expressing models.
  • Demonstrated favorable pharmacokinetics and a wide therapeutic index.
  • Showed minimal off-target toxicity, supporting safe administration.

Cite This Study

Rohila et al. (2026) studied this question.

synapsesocial.com/papers/69d1fd8ea79560c99a0a3a89https://doi.org/10.1158/1538-7445.am2026-5405
View Full Paper
Ask AI
Bookmark
Share